Amphastar Pharmaceuticals, Inc. (AMPH) Given Average Rating of “Buy” by Analysts
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has received a consensus recommendation of “Buy” from the eight research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $20.17.
Several analysts have recently weighed in on the stock. Jefferies Group LLC set a $21.00 price objective on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, April 20th. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, May 16th. Raymond James Financial, Inc. cut shares of Amphastar Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and lowered their price objective for the company from $21.00 to $18.00 in a research report on Tuesday, March 14th. TheStreet upgraded shares of Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Monday, June 26th. Finally, Needham & Company LLC decreased their target price on shares of Amphastar Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, March 14th.
COPYRIGHT VIOLATION WARNING: “Amphastar Pharmaceuticals, Inc. (AMPH) Given Average Rating of “Buy” by Analysts” was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/03/amphastar-pharmaceuticals-inc-amph-given-average-rating-of-buy-by-analysts.html.
Shares of Amphastar Pharmaceuticals (AMPH) traded up 0.39% on Monday, hitting $17.93. 136,940 shares of the stock traded hands. The firm has a market cap of $820.06 million, a P/E ratio of 94.37 and a beta of 1.68. The stock has a 50-day moving average price of $16.62 and a 200 day moving average price of $16.18. Amphastar Pharmaceuticals has a 52 week low of $12.05 and a 52 week high of $21.75.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Monday, May 8th. The company reported $0.03 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.06 by $0.03. The company had revenue of $56.67 million for the quarter, compared to analysts’ expectations of $63.74 million. Amphastar Pharmaceuticals had a net margin of 3.54% and a return on equity of 2.69%. The business’s quarterly revenue was down 4.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.12 EPS. Equities research analysts predict that Amphastar Pharmaceuticals will post $0.40 EPS for the current fiscal year.
In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $17.07, for a total value of $170,700.00. Following the sale, the director now owns 28,844 shares of the company’s stock, valued at approximately $492,367.08. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jason B. Shandell sold 11,482 shares of the firm’s stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $16.92, for a total transaction of $194,275.44. Following the completion of the sale, the director now directly owns 241,342 shares in the company, valued at approximately $4,083,506.64. The disclosure for this sale can be found here. In the last three months, insiders sold 43,982 shares of company stock worth $735,850. Insiders own 11.10% of the company’s stock.
A number of large investors have recently made changes to their positions in the company. Skandinaviska Enskilda Banken AB publ raised its stake in shares of Amphastar Pharmaceuticals by 24.3% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 216,600 shares of the company’s stock worth $3,141,000 after buying an additional 42,400 shares during the period. Tudor Investment Corp ET AL raised its stake in shares of Amphastar Pharmaceuticals by 33.9% in the first quarter. Tudor Investment Corp ET AL now owns 35,387 shares of the company’s stock worth $513,000 after buying an additional 8,960 shares during the period. Paloma Partners Management Co raised its stake in shares of Amphastar Pharmaceuticals by 90.4% in the first quarter. Paloma Partners Management Co now owns 58,746 shares of the company’s stock worth $852,000 after buying an additional 27,884 shares during the period. AQR Capital Management LLC raised its stake in shares of Amphastar Pharmaceuticals by 7.5% in the first quarter. AQR Capital Management LLC now owns 99,641 shares of the company’s stock worth $1,445,000 after buying an additional 6,912 shares during the period. Finally, State Street Corp raised its stake in shares of Amphastar Pharmaceuticals by 11.1% in the first quarter. State Street Corp now owns 1,062,439 shares of the company’s stock worth $15,406,000 after buying an additional 106,448 shares during the period. 45.20% of the stock is currently owned by institutional investors and hedge funds.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.